Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study

Robert L. Coleman, Wei Hu, Pamela Soliman, Alpa Nick, Pedro T. Ramirez, Shannon N. Westin, Michael E. Garcia, Zhifei Zhu, Julieta Palancia, Bryan M. Fellman, Ying Yuan, Prahlad Ram, Farideh Bischoff, Kathleen Schmeler, Diane Bodurka, Larissa A. Meyer, Anil K. Sood

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Purpose: To evaluate the effect of dasatinib therapy on EphA2 signaling in cancers of women with measurable (biopsy amenable) advanced-stage, chemo-naïve primary or recurrent endometrial cancer. Preliminary efficacy was also assessed. Patients and methods: We performed a pilot study of single-agent dasatinib lead-in, followed by triplet dasatinib, paclitaxel, and carboplatin. We measured the downstream effectors of EphA2 signaling in pre- and post-dasatinib treatment biopsy tissue samples; we also determined the severity of adverse events and patients' progression-free survival and overall survival durations. Results: Eighteen patients were recruited and given dasatinib (150 mg orally daily for 14 days), followed by paclitaxel, carboplatin and dasatinib (daily) for six cycles (21-day cycles). Seventeen patients were evaluable for toxicity and 11 patients for response. A reverse phase protein array and proximity ligation assay revealed that CRAF/BRAF dimerization, caveolin-1 level, and Notch pathway signaling were predictive of response and resistance to dasatinib. Overall, the objective response rate was 45% (95% CI: 17%–77%), with median progression-free survival duration of 10.5 months and median overall survival duration of 30.4 months. The most common grade 3 or 4 adverse events were neutropenia (76%), thrombocytopenia (53%), anemia (53%), and fatigue (12%). Conclusions: Caveolin-1 expression, in combination with CRAF/BRAF heterodimerization, is associated with resistance to EphA2 targeting by dasatinib. The triplet combination showed interesting clinical activity in endometrial cancer with acceptable toxicity. Pretreatment with dasatinib may accentuate combination therapy toxicity.

Original languageEnglish (US)
Pages (from-to)104-112
Number of pages9
JournalGynecologic oncology
Volume161
Issue number1
DOIs
StatePublished - Apr 2021

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study'. Together they form a unique fingerprint.

Cite this